Publication:
Outcome and management of uterine leiomyosarcoma treated following surgery for presumed benign disease: Review of literature

dc.contributor.authorTantitamit T.
dc.contributor.authorHuang K.-G.
dc.contributor.authorManopunya M.
dc.contributor.authorYen C.-F.
dc.date.accessioned2021-04-05T03:25:35Z
dc.date.available2021-04-05T03:25:35Z
dc.date.issued2018
dc.date.issuedBE2561
dc.description.abstractUterine leiomyosarcoma (uLMS) is a rare and aggressive cancer, usually diagnosed incidentally at the time of myomectomy or hysterectomy. There have been concerns for several years about the fact that the inadvertent disruption of occult uLMS may have a negative impact on patient outcome. This study reviews the outcome and management of patients with a diagnosis of uLMS after surgery for presumed benign disease. We conducted a literature search in which 47 published English-language articles were obtained for evaluation. A total of 23 studies with outcomes data were included. It is evidenced that patients who underwent surgery with tumor disruption resulted in poorer outcomes compared with en bloc tumor, especially by power morcellation. The power morcellation was associated with an increased risk of recurrence, shorten time to recurrence, and upstage after re-exploration. Early re-exploration and surgical staging are appreciated for better prognosis and may alter postoperative treatment. We also updated on the incidence and preoperative evaluation to assess the risk of patient and give an effective counseling. © 2018 Gynecology and Minimally Invasive Therapy | Published by Wolters Kluwer - Medknow.
dc.format.mimetypeapplication/pdf
dc.identifier.citationGynecology and Minimally Invasive Therapy. Vol 7, No.2 (2018), p.47-55
dc.identifier.doi10.4103/GMIT.GMIT-10-18
dc.identifier.issn22133070
dc.identifier.other2-s2.0-85046877592
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6112
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherCA 125 antigen
dc.subject.otherFluorodeoxyglucose
dc.subject.otherAbdominal hysterectomy
dc.subject.otherAntibody blood level
dc.subject.otherCancer prognosis
dc.subject.otherCancer risk
dc.subject.otherCancer staging
dc.subject.otherCancer survival
dc.subject.otherClinical effectiveness
dc.subject.otherColor Doppler flowmetry
dc.subject.otherConservative treatment
dc.subject.otherDisease marker
dc.subject.otherEchography
dc.subject.otherFemale
dc.subject.otherFemale fertility
dc.subject.otherHuman
dc.subject.otherIncidence
dc.subject.otherLeiomyosarcoma
dc.subject.otherMyomectomy
dc.subject.otherNuclear magnetic resonance imaging
dc.subject.otherOutcome assessment
dc.subject.otherPeak systolic velocity
dc.subject.otherPositron emission tomography
dc.subject.otherPreoperative evaluation
dc.subject.otherPriority journal
dc.subject.otherRecurrence risk
dc.subject.otherReproductive success
dc.subject.otherReview
dc.subject.otherRisk factor
dc.subject.otherSalpingooophorectomy
dc.subject.otherSurvival rate
dc.subject.otherTreatment outcome
dc.subject.otherTreatment response
dc.subject.otherTumor volume
dc.subject.otherUltrasound
dc.subject.otherUterine leiomyosarcoma
dc.subject.otherUterus disease
dc.subject.otherUterus sarcoma
dc.subject.otherUterus weight
dc.titleOutcome and management of uterine leiomyosarcoma treated following surgery for presumed benign disease: Review of literature
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046877592&doi=10.4103%2fGMIT.GMIT-10-18&partnerID=40&md5=e5fa66474d0b28e75483a2e6337dabeb

Files